Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Retigabine · 1 trial · 1 indication
Change from Baseline (BL) was calculated as the value of the average diary pain score for the last 7 days of the MP minus the value of the average pain score at BL (post wash-out period, including the average of the last 7 available entries prior to/including the diary pain measurement on Titration Day 0). Based on their pain experienced during the previous 24 hours, participants assessed their pain every evening at bedtime in an electronic diary by choosing the appropriate number on an 11-point Numerical Rating Scale (NRS): 0, no pain; 1 to 3, mild; 4 to 6, moderate; 7 to 10, severe pain.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Retigabine |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Retigabine | DRUG | 150mg/day up to 900mg/day |
| Placebo | DRUG | daily |
Inclusion Criteria: * Ability to provide informed consent * Male or female subjects * 18-85 years of age * PHN for more than 6 months after the healing of herpes zoster skin rash * Has a pain score at screening and randomization that qualifies Exclusion Criteria: * Other significant pain that may...
Retigabine is an investigational small molecule being studied for the treatment of postherpetic neuralgia, a type of nerve pain that occurs after a shingles infection. It is currently in Phase 2 clinical development for this condition.
Retigabine is being developed by Bausch Health Companies Inc. (NYSE: BHC). The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with postherpetic neuralgia.
Retigabine is in Phase 2 clinical development for postherpetic neuralgia. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, with no active trials currently ongoing.
Retigabine has been studied in one completed Phase 2 clinical trial, NCT00612105, which evaluated its safety and efficacy compared to placebo in 187 patients with postherpetic neuralgia. The trial was conducted in the United States and South Africa.
Retigabine is also known as ezogabine. The drug has been studied under both names in clinical trials for postherpetic neuralgia and other pain conditions.